Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Oncopeptides Innovation AB
AB
Active
Org 5593798795
Luntmakargatan 46, 111 37
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2022 · 4 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Oncopeptides Innovation AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
5M
4M
2M
1M
0M
2022: 0M
0M
2022
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 4M
4M
2024
EBITDA
SEK millions
5M
4M
2M
1M
0M
2022: 0M
0M
2022
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 4M
4M
2024
Income statement
SEK thousands
Item
2024
2023
2022
2022
Revenue
4 481
0
0
0
Staff expenses
—
—
−0
—
EBITDA
4 479
−1
−5
−5
Depreciation & amort.
−21 472
−0
−0
−0
EBIT
−16 993
−1
−5
−5
Net financials
−12 240
1
0
—
Profit before tax
0
−1
−5
−5
Tax
−0
−0
−0
−0
Net profit
0
−1
−5
−5
Balance sheet
SEK thousands
Item
2024
2023
2022
2022
Total assets
534 281
7 020
45
45
Equity
19
19
20
20
Long-term debt
440 112
0
0
0
Short-term debt
94 150
7 001
25
25
Total debt
534 262
7 001
25
25
Financial ratios
5-year trend
EBITDA margin
100,0 %
This company
15,8 %
Market median
This company
Market median
533% above market
2022
2024
Equity ratio
0,0 %
This company
38,2 %
Market median
This company
Market median
100% below market
2022
2024
Return on equity
0,0 %
This company
18,4 %
Market median
This company
Market median
100% below market
2022
2024
Net profit margin
0,0 %
This company
8,1 %
Market median
This company
Market median
100% below market
2022
2024
Asset turnover
0,01×
This company
1,12×
Market median
This company
Market median
99% below market
2022
2024
Debt / equity
>999×
This company
0,62×
Market median
This company
Market median
>999% above market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-05-10 – 2022-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-05-01 – 2022-12-31
View
PDF
More on Oncopeptides Innovation AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
